Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients
Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients
The primary purpose of this study is to investigate the effectiveness of antidepressants on
 the treatments for non-psychotic major depressive disorder (MDD) in Korea. The study divides
 MDD patients into 3 level groups according to their past histories to treatments and compares
 the effectiveness of various treatment regimens at each level.

 The treatment level groups are: 1) patients who have never been treated with appropriate
 medications for their current depressive symptoms before, 2) who received an appropriate SSRI
 (Selective Serotonin Reuptake Inhibitor) once but did not respond to it, 3) who received two
 types of SSRI antidepressant treatments without much effects in reducing their depressive
 symptoms.

 The first level group will be treated with a single SSRI antidepressant treatment. The second
 and third level groups, who received SSRI treatment before, will be treated with alternative
 SSRI antidepressants (switching), combined multiple SSRI treatments (antidepressant
 combination), or SSRI treatments combined with mood stabilizer or anti-psychotics
 (augmentation). This study does not use placebos. Patients will visit 5 times for 6 weeks at
 each level for treatments. Patients will be evaluated for the severity of depressive
 symptoms, functional level, and side effects at each visit. Afterwards, the investigations
 will combine to monitor the patients depressive symptoms in every 3 months for the next 24
 months. 18 nationwide university hospitals will participate in this study. This multi-site,
 prospective, and naturalistic study for patients with depression in Korea is a main project
 of 'Clinical Research Center for Depression' funded by the Ministry for Health, Welfare, and
 Family Affairs (MIHWAF) in Korea for a highly-qualified research achievement.
Patients will be classified into 3 levels by their past therapeutic histories:

 Level 1: Patients who do not receive an appropriate treatment for their current major
 depressive episode.

 Level 2: Patients who never showed a satisfactory response to an adequate dosage of
 Paroxetine during a sufficient period of their current major depressive episode.

 Level 3: Patients without a satisfactory response to two or more antidepressants including
 one of Paroxetine or Escitalopram for a sufficient period.

 A satisfactory response means baseline HAM-D17 score was reduced over 50% or HAM-D17 score 10
 or below and a sufficient period means 6 weeks.

 Patients will be randomly assigned to the following treatment groups. Patients in level 1
 will be randomly assigned to treatment groups among Paroxetine monotherapy, Escitalopram
 monotherapy, or Venlafaxine monotherapy.

 Patients in level 2 will be enrolled who were medicated Paroxetine monotherapy in level 1 and
 assigned to one of the following 4 groups; Escitalopram monotherapy, Venlafaxine monotherapy,
 Paroxetine combined with Venlafaxine, or Paroxetine augmented with Lithium.

 Patients in level 3 will be randomly assigned to one of the following 4 groups: 1) Either
 Paroxetine combined with Lamotrigine or Paroxetine combined with Bupropion if they resist two
 antidepressants including Paroxetine. 2) Either Escitalopram combined with Mirtazapine or
 Escitalopram combined with Aripiprazole if they resist two antidepressants including
 Escitalopram. 3) Patients who does not respond to both Paroxetine and Escitalopram will be
 randomly assigned to either 1) or 2).
Inclusion Criteria:

 -  Clinical diagnosis of non-psychotic Major depressive disorder

 -  HAMD-17 score 14 or greater

 -  Age of 18 or greater and 65 or less

 Exclusion Criteria:

 -  patients with current or past history of diagnosis of bipolar disorder, schizophrenia,
 schizoaffective disorder, or psychotic disorder NOS

 -  patients with current psychotic features, eating disorders or obsessive-compulsive
 disorder

 -  patients with neurological disorder

 -  patients with medical condition that could interfere with everyday life activities

 -  pregnant or lactating women,

 -  patients with current other DSM-IV TR Axis I diagnosis other than MDD which needs
 inpatient care

 -  patients who treated with ECT for current depressive episode

 -  insufficient information of past treatment for current depressive episode

 -  patients who posed a serious suicidal risk.